Department of Gynecology and Obstetrics, Klinikum St. Marien Amberg, Amberg, Germany.
Tumor Center, University of Regensburg, Regensburg, Germany.
J Cancer Res Clin Oncol. 2019 May;145(5):1369-1376. doi: 10.1007/s00432-019-02890-7. Epub 2019 Mar 18.
The lack of prognostic data impedes implementation of optimal therapy for cervical cancer. For instance, recommended therapy for FIGO IIB cervical cancer is radical hysterectomy or radiochemotherapy. To enlighten different therapeutic approaches, we investigated the benefit of individual therapies or combination thereof in patients with or without infested lymph nodes.
The German Tumor Centre Regensburg registered 389 patients with FIGO IIB, IIIA, IIIB, and IVA cervical cancer between 2002 and 2015. We estimated hazard ratios (HR) for overall survival against different therapies using univariable and multivariable cox regression. After risk adjustment with respect to clinicopathological parameters, we performed model selection using conditional stepwise reverse selection.
We demonstrated the need for thorough assessment of the nodal status to obtain reliable data for treatment strategy. Our analysis showed significant differences for overall survival in FIGO IIB depending on therapy and nodal status. Outcome was inferior with radiochemotherapy without surgery for patients with N0 compared to surgery and radiochemotherapy combined (HR 3.012; 95% CI 1.075-8.441; p = 0.036); however, for N1, radiochemotherapy without surgery resulted in comparable outcome (HR 0.808; 95% CI 0.189-3.403; p = 0.765), whereas surgery alone yielded in poor outcome (HR 2.889; 95% CI 1.356-6.156; p = 0.006). Regardless of the nodal status, chemotherapy was superior in advanced stage cervical cancer FIGO III to IVA.
Our study suggests that in terms of oncological outcome FIGO IIB cervical cancer patients benefit from a combination of surgery and radiochemotherapy. However, in the presence of lymph node infestation, surgery does not add substantial benefit to the patient.
缺乏预后数据阻碍了宫颈癌最佳治疗方案的实施。例如,FIGO IIB 宫颈癌的推荐治疗方法是根治性子宫切除术或放化疗。为了阐明不同的治疗方法,我们研究了有无淋巴结受累患者接受单一治疗或联合治疗的获益。
德国雷根斯堡肿瘤中心于 2002 年至 2015 年期间登记了 389 例 FIGO IIB、IIIA、IIIB 和 IVA 期宫颈癌患者。我们使用单变量和多变量 COX 回归分析评估不同治疗方法的总生存风险比(HR)。在根据临床病理参数进行风险调整后,我们使用条件逐步反向选择进行模型选择。
我们证明需要彻底评估淋巴结状态,以获得可靠的治疗策略数据。我们的分析表明,FIGO IIB 期宫颈癌的总生存率因治疗方法和淋巴结状态而异。对于 N0 患者,单纯放化疗的结果不如手术联合放化疗(HR 3.012;95%CI 1.075-8.441;p=0.036),而对于 N1 患者,单纯放化疗的结果可与手术联合放化疗相媲美(HR 0.808;95%CI 0.189-3.403;p=0.765),而单纯手术则预后不良(HR 2.889;95%CI 1.356-6.156;p=0.006)。无论淋巴结状态如何,在 FIGO III-IVA 期宫颈癌中,化疗均优于手术。
我们的研究表明,在肿瘤学结果方面,FIGO IIB 期宫颈癌患者从手术和放化疗联合治疗中获益。然而,在存在淋巴结受累的情况下,手术对患者没有显著益处。